Search - tctmd.com

Displaying 1 - 20 of 143

Sort: Relevancy | Date

Year in Review: Top Prevention Stories of 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Evolocumab Wins for Primary Prevention in VESALIUS-CV

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

October 03, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 27, 2024

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

Top Coronary Artery Disease News of 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

November 17, 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

November 13, 2023

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

September 19, 2023

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.